SCHEMBL15524735

SCHEMBL15524735

O=C(O)N(CCO)Cc1ccc(Nc2ncc(C(F)(F)F)c(Cl)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 11/20 0.45
▸ GSK3A P49840 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ AURKA O14965 1/20 0.42
▸ CNR2 P34972 1/20 0.41
▸ KDR P35968 2/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ STK17A Q9UEE5 1/20 0.40
▸ JAK3 P52333 2/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ PTK2B Q14289 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40
▸ CDC7 O00311 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524373 0.88 PTK2 (0.43) PTK2GSK3AGSK3BAURKAKDR
SCHEMBL1627493 0.81 AURKA (0.52) PTK2GSK3AGSK3BAURKACNR2
SCHEMBL1917462 0.79 FFAR1 (0.52) PTK2GSK3AGSK3BAURKACNR2
SCHEMBL15524764 0.79 CNR2 (0.54) PTK2GSK3AGSK3BAURKACNR2
SCHEMBL15524665 0.78 GSK3A (0.40) PTK2GSK3AGSK3BCNR2JAK3
SCHEMBL15524664 0.78 PTK2 (0.65) PTK2
SCHEMBL579089 0.77 GSK3B (0.70) PTK2GSK3AGSK3BAURKAJAK3
SCHEMBL4393743 0.77 GSK3A (0.53) PTK2GSK3AGSK3BAURKASTK17A
SCHEMBL30002940 0.76 GSK3A (0.51) PTK2GSK3AGSK3BAURKACNR2
SCHEMBL2637214 0.76 PTK2 (0.49) PTK2GSK3AGSK3BAURKACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266864-B2 VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-02-23 — — US disclosed
US-20150225377-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2015-08-13 — — US disclosed
US-20140080798-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225377-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR PTK2 240/4885GSK3A 446/4885GSK3B 283/4885
US-20140080798-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR PTK2 260/4885GSK3A 419/4885GSK3B 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback